Clinical research


Reduction of complement activation and renal dysfunction with PMMA-based CVVH treatment in sepsis-induced AKI

New relevant findings on the role of polymethylmethacrylate (PMMA)-based CVVH in an animal model of sepsis-induced AKI have been published in Frontiers in Immunology. The results show that PMMA-based CVVH significantly reduces tissue and systemic complement activation limiting renal damage and fibrosis highlighting the potential role of PMMA membrane as a therapeutic strategy in patients with septic acute kidney injury (AKI).


Survival Benefit of Polymyxin B Hemoperfusion in Septic Shock Patients Requiring Noradrenaline

Results from the Nationwide Administrative Database in Japan concerning adults diagnosed with septic shock and requiring noradrenaline support during the period 2016-2019 have been published in the Blood Purification journal by Fujimori and co-workers.


COVID-19 and Polymyxin B Hemoperfusion – Data from the EUPHAS-2 registry

Polymyxin B hemoperfusion experience from critically ill COVID-19 patients with endotoxic shock has been published recently in Artificial Organs. The study refers to 12 COVID-19 patients hospitalized in ICU who developed a secondary infection – endotexemia leading to septic shock status and whose data were collected in the observational study EUPHAS 2 from February to May 2020, showing very interesting results.


Critically ill COVID-19 patients and the role of Polymyxin B hemoperfusion

Over the last year, various works in literature have revealed the potential role of Polymyxin B Hemoperfusion in the management of non-responsive COVID-19 patients admitted to intensive care. We report here various case reports that have been presented as abstracts at international congresses and/or published in peer-reviewed journals on the use of Polymyxin B hemoperfusion in COVID-19 patients.


EUPHRATES Trial Publication

A new article concerning EUPHRATES trial results has been published in Intensive Care Medicine. This Post Hoc analysis follows the results concerning the Overall Population, published previously in JAMA.
This marks another step forward in septic shock research and in the accumulation of evidence for Polymyxin B hemoperfusion as precision therapy in selected patients.



At the 35th VICENZA COURSE on AKI and CRRT organized by Professor Claudio Ronco, held in Vicenza 13th–16th June, Professor Massimo Antonelli, President of the European Society of Intensive Care Medicine (ESICM) and member of the EUPHRATES trial steering committee, will present results from the EUPHRATES trial on Polymyxin B hemoperfusion in septic shock patients on 14th June at 17.30.



The fourth and final module of PMA application for FDA approval of Toraymyxin® has been submitted. A further data analysis of the EUPHRATES database identifies a population with significant mortality benefit when treated with Polymyxin B hemoperfusion therapy.



EUPHRATES, an RCT performed in the USA and Canada on Polymyxin B hemoperfusion therapy (Toraymyxin®) has finished enrolment and the first results on the primary endpoints have recently been announced in a press release.



EUPHAS 2 is a web-based registry for the collection of clinical data from patients undergoing Polymyxin B hemoperfusion therapy (Toraymyxin®). Data from 357 patients recorded during the first phase have been published recently in Annals of Intensive Care Medicine.